KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Inventory (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 14 years of Inventory data on record, last reported at $3.2 billion in Q4 2025.

  • For Q4 2025, Inventory rose 3.68% year-over-year to $3.2 billion; the TTM value through Dec 2025 reached $3.2 billion, up 3.68%, while the annual FY2025 figure was $3.2 billion, 3.68% up from the prior year.
  • Inventory reached $3.2 billion in Q4 2025 per REGN's latest filing, down from $3.3 billion in the prior quarter.
  • Across five years, Inventory topped out at $3.3 billion in Q3 2025 and bottomed at $2.0 billion in Q2 2021.
  • Average Inventory over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2023.
  • Peak YoY movement for Inventory: skyrocketed 46.17% in 2021, then decreased 8.0% in 2022.
  • A 5-year view of Inventory shows it stood at $2.1 billion in 2021, then increased by 16.95% to $2.4 billion in 2022, then rose by 7.44% to $2.6 billion in 2023, then increased by 19.64% to $3.1 billion in 2024, then grew by 3.68% to $3.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $3.2 billion in Q4 2025, $3.3 billion in Q3 2025, and $3.2 billion in Q2 2025.